Cancer drug combo study pulled before starting
NCT ID NCT06597734
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This study was designed to test whether adding olutasidenib to standard chemotherapy (hypomethylating agents) could help control certain blood cancers with an IDH1 mutation, including myelodysplastic syndromes, chronic myelomonocytic leukemia, and advanced myeloproliferative neoplasms. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to manage the disease rather than cure it, as ongoing treatment would likely be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.